Pay in 4 interest-free payments of $5.63 Learn more
Ships within 48 hours · Estimated delivery Aug 20 - Aug 25
Heres why this matters 1 First-Mover Advantage in a Blockbuster Molecule Ready to launch immediately upon patent expiry Early entry = potential market share dominance Targeting both Type-2 diabetes & obesity 2 Massive Price Disruption Expected Current therapy cost: 8,00016,000/month Expected generic pricing: 4,0005,000/month Industry estimates suggest prices may fall 5065% over time In a largely out-of-pocket market like India, price is access
But food triggers the release of stomach acids and digestive enzymes that can break the drug down before absorption occurs
"We don't know which countries (Semagcare is sold to) but we are doing the promotion because once they sell more, we sell more API (active pharmaceutical ingredient) to them," he told Reuters when asked about why it was showcasing the drug at the expo
Most DPP4 inhibitors have names that end with 'gliptin'
US$ 25.27
US$ 22.99
US$ 22.26
US$ 24.52
US$ 19.99
US$ 28.29
US$ 25.68
US$ 21.24
